KRAS and non-small cell lung carcinoma: And two of them, sotorasib and adagrasib, have got accelerated approvals by FDA for clinical use in adult patients with KRAS G12C‐mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy (thus second‐ or later‐line therapies), based on phase 1/2 clinical trials CodeBreaK 100[16] and KRYSTAL‐1,[17] respectively.